Medrx Co

Medrx Co OCF/Debt

The Operating Cash Flow to Debt Ratio of Medrx Co (4586.T) as of Oct 17, 2026 is -1,970.71 %. In the previous year, Operating Cash Flow to Debt Ratio was -307.69 % — a change of 540.48% (lower).

OCF/Debt

-1,970.71 %

YoY

540.48%

Last updated:

Operating Cash Flow to Debt Ratio of Medrx Co is 2020 -1,970.71 % . Operating Cash Flow to Debt Ratio of Medrx Co was 2019 -307.69 % . It decreases by 540.48% lower compared to the previous year.

The Medrx Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2016
-307.69 JPY
Jan 1, 2020
-1,970.71 JPY
The Medrx Co OCF/Debt history
YEAROCF/DebtYoY
-1,970.71 %+540.48%
-307.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co Ltd is a pharmaceutical company based in Higashikagawa-shi, Japan, operating within the Health Care sector. The company has 22 employees and went public on February 13, 2013, with its ticker listed as 4586.T on the Tokyo Stock Exchange. Medrx focuses on pharmaceutical drug development utilizing transdermal absorption technology. The company's website is www.medrx.co.jp. Medrx develops new medicines using percutaneous absorption formulation technology, specifically employing ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). These technologies leverage ionic liquid characteristics and nano colloidization to enhance drug efficacy, minimize side effects, and provide alternative administration methods for patients who cannot take medications orally. The company aims to create medicines with innovative value by addressing challenges such as patient compliance and delivery methods for difficult-to-administer drugs. Medrx is headquartered in Higashikagawa-shi, Kagawa Prefecture, and maintains a small operational scale with a dedicated team of 22 full-time employees. The company's business model centers on developing pharmaceuticals that improve patient outcomes through advanced transdermal delivery systems, targeting specific medical needs where traditional oral administration is impractical or ineffective. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Operating Cash Flow to Debt Ratio of Medrx Co is -1,970.71 % in 2020.

Operating Cash Flow to Debt Ratio of Medrx Co changed from -307.69 % to -1,970.71 %, representing a 540.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Medrx Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Medrx Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Medrx Co

All Key Metrics — Medrx Co